Skip to main content

Viridian Therapeutics, Inc. (VRDN)

NASDAQ: VRDN · IEX Real-Time Price · USD
16.18 -0.51 (-3.06%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap279.57M
Revenue (ttm)2.60M
Net Income (ttm)-132.66M
Shares Out8.11M
EPS (ttm)-24.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume19,937
Open16.50
Previous Close16.69
Day's Range15.96 - 16.50
52-Week Range7.09 - 25.67
Beta1.09
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 9, 2021

About VRDN

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in...

IndustryBiotechnology
Founded2006
CEOWilliam Marshall
Employees26
Stock ExchangeNASDAQ
Ticker SymbolVRDN
Full Company Profile

Financial Performance

In 2020, VRDN's revenue was $1.05 million, a decrease of -76.46% compared to the previous year's $4.46 million. Losses were -$110.72 million, 164.4% more than in 2019.

Financial Statements

News

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment...

- VRDN-001 program remains on track for key proof of concept clinical data in Thyroid Eye Disease patients in the second quarter of 2022 -

1 week ago - GlobeNewsWire

Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American...

WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...

3 weeks ago - GlobeNewsWire

Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise...

WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...

4 weeks ago - GlobeNewsWire

Why Are Viridian Therapeutics Shares Moving Higher On Tuesday?

Viridian Therapeutics Inc (NASDAQ: VRDN) has priced an underwritten public offering with approximately $85.0 million gross proceeds.  Viridian will offer 6.18 million shares at $11.00 per share, and 23,...

1 month ago - Benzinga

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock

WALTHAM, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...

1 month ago - GlobeNewsWire

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...

1 month ago - GlobeNewsWire

Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company advancing new treatments for patients suffering fr...

2 months ago - GlobeNewsWire

Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer

BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but unders...

2 months ago - GlobeNewsWire

Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee

BOULDER, Colo., July 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but unders...

3 months ago - GlobeNewsWire

Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference

BOULDER, Colo., June 10, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but unders...

4 months ago - GlobeNewsWire

Viridian Therapeutics to Participate in Upcoming Investor Conferences

BOULDER, Colo., May 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underse...

5 months ago - GlobeNewsWire

Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

BOULDER, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underse...

5 months ago - GlobeNewsWire

Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates

BOULDER, Colo., March 25, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...

6 months ago - GlobeNewsWire

Earnings Preview: Viridian Therapeutics

Viridian Therapeutics (NASDAQ:VRDN) releases its next round of earnings this Thursday, March 25. Here is Benzinga's essential guide to Viridian Therapeutics's Q4 earnings report.

6 months ago - Benzinga

Will Viridian Therapeutics, Inc. (VRDN) Report Negative Earnings Next Week? What You Should Know

Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update

BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...

7 months ago - GlobeNewsWire

Will Viridian Therapeutics, Inc. (VRDN) Report Negative Q4 Earnings? What You Should Know

Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Viridian Therapeutics to Present at Three Upcoming Investor Conferences

BOULDER, Colo., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President and Ch...

8 months ago - GlobeNewsWire

Alphabet, Apple, Roku, Tesla and More Monday Afternoon Analyst Calls

With the trading day about half over, the broad markets had pulled back on Monday.

8 months ago - 24/7 Wall Street

miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including...

BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“V...

9 months ago - GlobeNewsWire